Stoke Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $2.91M beats by $0.19M
- Stoke Therapeutics press release (NASDAQ:STOK): Q3 GAAP EPS of -$0.66 beats by $0.02.
- Revenue of $2.91M beats by $0.19M.
- As of September 30, 2022, Company had $252.2M in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fund operations into 2025.